Gyeongsang National University Hospital Registry
Launched by GYEONGSANG NATIONAL UNIVERSITY HOSPITAL · Dec 1, 2020
Trial Information
Current as of September 27, 2025
Recruiting
Keywords
ClinConnect Summary
The Gyeongsang National University Hospital Registry is a study that looks at patients who have undergone a procedure called percutaneous coronary intervention (PCI), which is used to open blocked arteries in the heart. This registry aims to understand how well patients do over the long term after having this procedure and to identify factors that may lead to complications. The study is taking place at two hospitals in South Korea and has been enrolling patients since January 2010.
To participate in this study, you need to be at least 18 years old and have significant coronary artery disease that has been treated with PCI. The study is open to all genders and focuses on gathering information about patients' health after their treatment. If you join, you can expect to provide some health measurements and possibly help researchers learn more about improving care for heart disease patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years
- • Significant coronary artery disease
- • Treated with PCI
- • Multiple hemostatic or physiologic measurements
- Exclusion Criteria:
- • Medically treated cases
About Gyeongsang National University Hospital
Gyeongsang National University Hospital is a leading medical institution located in Jinju, South Korea, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of clinical studies, the hospital emphasizes a multidisciplinary approach, collaborating with various departments to enhance patient care and contribute to medical knowledge. With a commitment to ethical standards and patient safety, Gyeongsang National University Hospital aims to facilitate the development of new therapies and interventions, ultimately improving health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Changwon, Gyeongsangnam Do, Korea, Republic Of
Jinju, Gyeonsangnam Do, Korea, Republic Of
Patients applied
Trial Officials
Young-Hoon Jeong, MD, PhD
Study Director
Changwon Gyeongsang National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials